Medical Industry Feature

Guest: Michael Kaplitt, MD, PhD For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The results were groundbreaking and paved new avenues for research in neurological gene therapy, such as preventative intervention. Join health and science journalist Catherine Price as she speaks with Dr. Michael Kaplitt, Executive Vice Chair of the Department of Neurological Surgery at NewYork-Presbyterian/Weill Cornell Medicine, as he discusses the story of his breakthrough and how he’s continuing to evolve the field of neurosurgery. © 2024 NewYork-Presbyterian

Guest: Pierre Elias, MD In this episode, you’ll gain insights into Dr. Elias’ innovative approach, integrating technology, data science, and medicine to develop algorithms that aim to enhance accuracy in predicting cardiovascular disease while allowing them to focus on providing personalized care to their patients. This could even help diagnose patients before symptoms occur. Join health and science journalist Catherine Price as she speaks with Dr. Pierre Elias, Medical Director of Artificial Intelligence at NewYork-Presbyterian, about the future of technology in medicine. © 2024 NewYork-Presbyterian

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Arnaud Bourdin, MD, PhD Since many severe asthma patients have been shown to have mucus plugs, it’s important to understand the role they plan in severe asthma. Join us as we discuss an exploratory study and the role of mucus plugging in severe asthma with Dr. Charles Turck and Professor Arnaud Bourdin. Professor Bourdin is the Head of Pulmonology at the Arnaud de Villeneuve Hospital in Montpellier, France. TEZSPIRE is a registered trademark of Amgen Inc. and AstraZeneca.©2024 Amgen and AstraZeneca. All rights reserved. US-83499 Last Updated 1/24

Guest: Christopher Petit, MD Pulmonary vein stenosis (PVS) is a rare and challenging heart condition, which narrows blood vessels around the lungs and typically impacts newborn children. Historically, the rates of survival have been low, but with Dr. Petit leading the development of innovative techniques and treatments, the trajectory of patients’ lives could positively change. Join health and science journalist Catherine Price and Dr. Christopher Petit, Co-Director of Children’s Heart Center at NewYork-Presbyterian Morgan Stanely Children’s Hospital and Division Chief of Pediatric Cardiology at Columbia University, to discuss breakthroughs and treatments that are making a big impact on pediatric survival rates. © 2024 NewYork-Presbyterian

Guest: Conor Liston, MD, PhD For patients diagnosed with depression for the first time the recommended course of treatment is the same; however, there’s a large patient population for whom these treatments won’t work. So it became increasingly important for Dr. Liston to map the brains of people suffering from major depression to see how it was impacting brain structures and symptoms. The research showed that certain networks expanded in the brains of patients who had depression and pushed into other networks. Learn more about identifying how these symptoms impact the patient’s brains, analyzing the best course for treatments, and how this research could be the key to effectively using transcranial magnetic stimulation to help patients with treatment-resistant depression. Join health and science journalist Catherine Price as she speaks with Dr. Conor Michael Liston, Psychiatrist at NewYork-Presbyterian/Weill Cornell Medicine, to discuss these approaches to help treatment-resistant depression. © 2024

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jamie Koprivnikar, MD Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health. REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.© 2024 Bristol-Myers Squibb Company2007-US-2300376 03/24

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Arnaud Bourdin, MD, PhD It’s only been a recent discovery that mucus plugging may be present and persistent in chronic severe asthma.1 In fact, studies have shown that mucus plugs may drive some lung function deficits in severe asthma.1 Given this recent finding, Dr Charles Turck speaks with Professor Arnaud Bourdin about the clinical significance and pathogenesis of mucus plugging in severe asthma. Professor Bourdin is Head of Pulmonology at Arnaud de Villeneuve Hospital in Montpellier, France. Reference: Dunican EM, Watchorn DC, Fahy JV. Ann Am Thorac Soc. 2018;15(Suppl 3):S184-S191. doi:10.1513/AnnalsATS.201807-485AW ©2024 Amgen and AstraZeneca. All rights reserved. US-86740 Last Updated 3/24

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Brian Iacoviello, MD Since the thinking part of depression may involve getting stuck on the sad or the negative thoughts, there is a need to focus on not just cognitive control for information but for emotional information processing.1 And that fits with the picture that we get from brain imaging research that shows hyperactivity in the emotion-processing region of the brain and a quieting-down of the cognitive control region of the brain when people are depressed.1 To take a deep dive, join Dr. Brian Iacoviello, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City. Reference Iacoviello BM, Wu G, Alvarez E, et al. Cognitive-emotional training as an intervention for major depressive disorder. Depress Anxiety. 2014;31(8):699-706. January 2024 US.UNB.X.23.00076

Guest: Aderonke Pederson, MD Major depressive disorder is a mental health condition that affects millions of Americans,1 and for the past several decades, treatment has consisted mainly of antidepressant therapy and psychotherapy.2,3 However, many patients still don't achieve their treatment goals and there are many potential barriers to accessing treatment. Learn more about these unmet needs in major depressive disorder care that underscore the importance of finding new treatment approaches with Dr. Aderonke Pederson, Assistant Professor of Psychiatry at Harvard Medical School. References: National Institute of Mental Health. Major depression. National Institute of Mental Health. July 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/statistics/major-depression National Institute of Mental Health. Depression. National Institute of Mental Health. September 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/topics/depression American Psychiatric Association. Practice g

Host: Jennifer Caudle, DO Guest: Manpreet Mundi, MD Enteral nutrition intolerance is quite prevalent as it can be seen in up to 40 percent of patients who are tube fed. Due to the significant consequences of intolerance, there’s an urgency to manage patients symptoms, and one option that’s been shown to help is peptide-based tube feeding formulas. Joining Dr. Jennifer Caudle to talk about the management of enteral feeding intolerance with peptide-based tube feeding formulas is Dr. Manpreet Mundi, Professor of Medicine in the Department of Endocrinology at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé

Guest: Richard Lafayette, MD, FACP Insights into the complement system are critical to our understanding of the pathogenesis of immunoglobin A (IgA) nephropathy.1 That’s why Dr. Richard Lafayette is here to share what we currently know about the complement system and its role in IgA nephropathy. Dr. Lafayette is a nephrologist at Stanford University Medical Center in California. References: Medjeral-Thomas NR, O'Shaughnessy MM. Adv Chronic Kidney Dis. 2020 Mar;27(2):111-119. doi: 10.1053/j.ackd.2019.12.004 319698 12/23

Guest: Jai Radhakrishnan, MD The most widely accepted mechanism for the pathogenesis of immunoglobin A (IgA) nephropathy is referred to as the “four-hit model,” which is a sequence of four events that can occur.1-3 Here to break down each of those four stages is Dr. Jai Radhakrishnan, a nephrologist at Columbia University Medical Center in New York. References: Knoppova B, Reily C, King RG, et al. J Clin Med. 2021;10(19):4501. doi:10.3390/jcm10194501 Maillard N, Wyatt RJ, Julian BA, et al. J Am Soc Nephrol. 2015;26(7):1503-1512. doi:10.1681/ASN.2014101000 Chang S, Li X-K. Front Med (Lausanne). 2020;7:92. doi:10.3389/fmed.2020.00092 319698 12/23

Guest: Mark Haas, MD Kidney biopsy is the gold standard for the diagnosis of immunoglobin A (IgA) nephropathy and complement 3 glomerulopathy (C3G),1,2 and the accurate interpretation of kidney biopsy findings is important not only for diagnosis but also guiding clinical management of these conditions. Learn more about what the diagnostic process and findings for IgA nephropathy and C3G look like with Dr Mark Haas, a renal pathologist at Cedars-Sinai Medical Center in Los Angeles. References: Mehdi A, Taliercio JJ. Cleve Clin J Med. 2023;90(6)(suppl 1):e1-e4. doi:10.3949/ccjm.90.e-s1.02 Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Nephron. 2020;144(6):272-280. doi:10.1159/000507254 319698 12/23

Guest: Pamela Kushner, MD, FAAFP The Cardio-Renal-Metabolic (CRM) systems are physiologically interconnected, and each one relies on energy homeostasis tofunction properly. So why is it important for clinicians to understand the CRM continuum to identify and assess comorbidities in order to effectively treat patients with heart failure? Dive into this episode with Dr. Pam Kushner, Clinical Professor at the University of California at Irvine, a Clinical Trialist, past Chair of the American Academy of Family Physicians Drugs and Devices Committee, and a Family Medicine Doctor with a private practice in Long Beach, California.

Guest: Stephen Greene, MD In 2022, the American Heart Association, American College of Cardiology, and Heart Failure Society of America created a joint guideline for the management of heart failure. Explore what the recommendations say and how they can help improve patient outcomes with Dr. Stephen Greene, an advanced heart failure specialist at Duke Heart Transplant Clinic and a cardiologist at Duke Cardiology Clinic in Durham, North Carolina. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 6/23

Guest: Pamela Kushner, MD, FAAFP Clinicians may agree that several challenges exist in diagnosing heart failure because patients may present with nonspecific symptoms or may have comorbidities. So what factors are important to evaluate when detecting and diagnosing heart failure in patients? Join Dr. Pam Kushner, clinical professor at the University of California at Irvine, as she walks us through the answer to this and more.

Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN There are 4 stages of heart failure, ranging from being at risk for heart failure to having an advanced condition. So what key insights should we know about the ACC/AHA stages of heart failure and the NYHA heart failure functional classifications? Discover more with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation.

Guest: Stephen Greene, MD One of the most important things we know about heart failure is that it doesn’t affect everyone equally, especially when you consider heart failure with reduced ejection fraction versus preserved ejection fraction. Dive into the complex pathophysiology and pathoetiology surrounding heart failure and how it differs when ejection fraction is reduced versus when it’s preserved with Dr. Stephen Greene, an advanced heart failure specialist at Duke Heart Transplant Clinic and a cardiologist at Duke Cardiology Clinic in Durham, North Carolina. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 6/23

Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN Approximately 6.2 million adults in the US have heart failure (hf), and this number is projected to grow to more than 8 million by 2030. Knowing this alarming statistic, what do we need to know about the clinical characteristics of hf? Take a deep dive with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Amy Sehnert, MD With the FDA’s approval of CAMZYOS® (mavacamten), the first and only cardiac myosin inhibitor for symptomatic New York Heart Association (NYHA) class II-III adult patients, healthcare professionals and patients now have another treatment option that targets HCM at the source. Learn more about the clinical trial data that supported the FDA approval, and how healthcare professionals can prescribe CAMZYOS from Dr. Amy Sehnert, Vice President and Head of Cardiomyopathy and Heart Failure Clinical Development at Bristol Myers Squibb.